Compare NWGL & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWGL | BFRI |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | Macau | United States |
| Employees | N/A | 94 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 13.2M |
| IPO Year | 2022 | N/A |
| Metric | NWGL | BFRI |
|---|---|---|
| Price | $0.29 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | ★ 3.7M | 374.9K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.57 |
| 52 Week High | $1.82 | $1.21 |
| Indicator | NWGL | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 31.72 | 59.88 |
| Support Level | $0.19 | $0.77 |
| Resistance Level | $0.38 | $1.13 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.90 | 69.94 |
CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.